Long-range activation of FKBP51 transcription by the androgen receptor via distal intronic enhancers.
Androgen receptor (AR) is a ligand-controlled transcription factor frequently deregulated in prostate carcinomas. Since there is scarce information on the action of AR on the chromatin level, we have elucidated the molecular mechanisms underlying the androgen-dependent regulation of immunophilin FKBP51 in prostate cancer cells. In comparison to the canonical AR target PSA, FKBP51 is more rapidly and strongly induced by androgen, with the regulation occurring merely at the transcriptional level. FKBP51 locus harbors 13 in silico-predicted androgen response elements (AREs), with most of them located downstream from transcription start site (TSS) and capable of binding AR in vitro. Chromatin immunoprecipitation assays in VCaP and LNCaP prostate cancer cells indicate that activation of the locus by the AR relies on four major intronic sites, with the compound ARE-containing sites >or=90 kb downstream from the TSS playing critical roles. Binding of agonist-loaded AR onto these sites in vivo was accompanied with significant recruitment of RNA polymerase II and BRM-containing chromatin remodeling complexes to the FKBP51 locus, which resulted in changes in the histone density of the locus. Our results indicate that very distal AREs act as genuine and robust enhancers, highlighting the importance of long-range regulation of transcription by the AR.
Institute of Biomedicine/Medical Biochemistry, University of Kuopio, P.O. Box 1627, FI-70211 Kuopio, Finland.
Harri
H
Makkonen
Miia
M
Kauhanen
Ville
V
Paakinaho
Tiina
T
Jääskeläinen
Jorma J
JJ
Palvimo
D000726:Androgen Antagonists / Q000494:pharmacology; D000813:Anilides / Q000494:pharmacology; D001665:Binding Sites; D045744:Cell Line, Tumor; D002843:Chromatin / Q000737:chemistry / Q000378:metabolism; D042002:Chromatin Assembly and Disassembly; D004742:Enhancer Elements, Genetic; D015972:Gene Expression Regulation, Neoplastic; D006657:Histones / Q000032:analysis; D006801:Humans; D007438:Introns; D008297:Male; D015741:Metribolone / Q000494:pharmacology; D009570:Nitriles / Q000494:pharmacology; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000378:metabolism; D011944:Receptors, Androgen / Q000378:metabolism*; D022021:Tacrolimus Binding Proteins / Q000096:biosynthesis / Q000235:genetics*; D045165:Testosterone Congeners / Q000494:pharmacology; D014105:Tosyl Compounds / Q000494:pharmacology; D014158:Transcription, Genetic / Q000187:drug effects; D015533:Transcriptional Activation; D000099159:Tacrolimus Binding Protein 5
D000726:Androgen Antagonists; D000813:Anilides; D002843:Chromatin; D006657:Histones; D015741:Metribolone; D009570:Nitriles; D011944:Receptors, Androgen; D022021:Tacrolimus Binding Proteins; D045165:Testosterone Congeners; D014105:Tosyl Compounds; D000099159:Tacrolimus Binding Protein 5; C053541:bicalutamide